Smoking Cessation in Patients After Coronary Angiography
1 other identifier
observational
122
0 countries
N/A
Brief Summary
OBJECTIVES The goal of this study is to evaluate the self-achieved smoking cessation supported with cytisine smoking cessation and its' on platelet aggregation and prothrombotic state in patients after coronary angiography and PCI. BACKGROUND Cigarette smoking is a major risk factor of coronary artery disease (CAD). Smoking cessation is one of the most cost-effective intervention in lifestyle. Self-reported rates of smoking cessation are reasonably low. Cytisine is promising drug in support of smoking cessation. Smoking affects various components leading to arterial thrombosis, and the effect of smoking cessation on prothrombotic state and platelet aggregation is still under investigation GOAL To assess rates of smoking cessation in patients after coronary angiography and PCI and factors influencing success in smoking cessation To assess feasibility, safety and efficacy of cytisine in smoking patients To assess effect of smoking cessation on platelet aggregation in patients treated with clopidogrel and on prothrombotic state. METHODS A prospective nonrandomized observational study of patients after coronary angiography.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2014
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 5, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
January 30, 2017
CompletedFirst Submitted
Initial submission to the registry
February 25, 2021
CompletedFirst Posted
Study publicly available on registry
March 5, 2021
CompletedMarch 5, 2021
March 1, 2021
2.4 years
February 25, 2021
March 3, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Platelet aggregation in patient treated with clopidogrel after smoking cessation
Platelet reactivity measured with PRU
30-days
Secondary Outcomes (8)
Prothrombotic state
30-days
Cotinine
30-days
Thrombin potential
30-day
Thrombomodulin
30-days
PAI-1
30-days
- +3 more secondary outcomes
Other Outcomes (2)
Smoking cessation
30-days, 6-months, 12-months
Cytisine as smoking cessation aid
30-days
Eligibility Criteria
Patients with stable CAD and ACS admitted to the catheterization laboratory in the Department of Cardiology, Grochowski Hospital, Warsaw, Poland
You may qualify if:
- Patients after coronary angiography or PCI,
- Aged 18 years or older,
- Smoking at least 10 cigarettes a day
You may not qualify if:
- Pregnancy
- Criteria may vary in substudies
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD, Adjunct, Director of the Programme
Study Record Dates
First Submitted
February 25, 2021
First Posted
March 5, 2021
Study Start
August 5, 2014
Primary Completion
December 31, 2016
Study Completion
January 30, 2017
Last Updated
March 5, 2021
Record last verified: 2021-03